{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:00:18Z","timestamp":1791518418034,"version":"4.3.4"},"reference-count":32,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>In recent years, research efforts have resulted in a significant increase in the number of therapies available for kidney disease care [...]<\/jats:p>","DOI":"10.3390\/ijms26199556","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:38:55Z","timestamp":1759246735000},"page":"9556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Special Issue: \u201cPharmacological Strategies and Molecular Mechanisms Associated with the Novel Nephroprotective Treatments\u201d"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2168-702X","authenticated-orcid":false,"given":"Michele","family":"Provenzano","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy"},{"name":"Nephrology, Dialysis and Transplant Unit, \u201cSS. Annunziata\u201d Hospital, 87100 Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ndt\/gfz282","article-title":"Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease","volume":"35","author":"Fouque","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int."},{"key":"ref_3","unstructured":"GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709\u2013733."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","article-title":"Cardiovascular disease in chronic kidney disease","volume":"46","author":"Cherney","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Schunk, S.J., and Zimmermann, P. (2025). Cardiovascular Risk and Its Presentation in Chronic Kidney Disease. J. Clin. Med., 14.","DOI":"10.3390\/jcm14134567"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"STOPACEi Trial Investigators Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","article-title":"The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease","volume":"116","author":"Brewster","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-981-13-8871-2_15","article-title":"Role of Aldosterone in Renal Fibrosis","volume":"1165","author":"Shrestha","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"Wolf","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_12","unstructured":"Ksi\u0105\u017cek, K., Wi\u015bniewska, M., Rogalska, A., Soko\u0142owska, M., Czarnecka, J., Wajda, A., and Kr\u00f3l, E. (2023). Novel pharmacological approaches to renin\u2013angiotensin\u2013aldosterone system inhibition: Current and future perspectives. Int. J. Mol. Sci., 24."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/ndt\/gfae216","article-title":"Upcoming drug targets for kidney protective effects in chronic kidney disease","volume":"40","author":"Nardone","year":"2025","journal-title":"Nephrol Dial Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/MNH.0000000000001067","article-title":"Targeting aldosterone to improve cardiorenal outcomes: From nonsteroidal mineralocorticoid receptor antagonists to aldosterone synthase inhibitors","volume":"34","author":"Helmeczi","year":"2025","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MNH.0000000000001089","article-title":"Aldosterone synthase inhibition in chronic kidney disease","volume":"34","author":"Theodorakopoulou","year":"2025","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.2215\/CJN.0000000000000540","article-title":"Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease","volume":"19","author":"Zachariah","year":"2024","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","unstructured":"Hou, Y., Li, Y., Tang, X., Chen, Q., Sun, Y., Wu, Y., and Zhang, Z. (2023). Indoxyl sulfate induces renal fibrosis via ROS-mediated activation of the NLRP3 inflammasome in mice. Int. J. Mol. Sci., 24."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","article-title":"Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease","volume":"132","author":"Burnier","year":"2023","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/ndt\/gfae041","article-title":"A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension","volume":"39","author":"Sarafidis","year":"2024","journal-title":"Nephrol Dial Transplant."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1574887115999201027145406","article-title":"Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio as Biomarkers for Cardiovascular Surgery Procedures: A Literature Review","volume":"16","author":"Serra","year":"2021","journal-title":"Rev. Recent. Clin. Trials"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10157-021-02153-1","article-title":"Calcium channel blocker in patients with chronic kidney disease","volume":"26","author":"Ohno","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"F548","DOI":"10.1152\/ajprenal.00233.2021","article-title":"Questioning the renoprotective role of L-type calcium channel blockers in chronic kidney disease using physiological modeling","volume":"321","author":"Moore","year":"2021","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hajdys, J., Fularski, P., Leszto, K., Majchrowicz, G., Stabrawa, M., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). New Insights into the Nephroprotective Potential of Lercanidipine. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241814048"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Chen, L., Lv, X., Kan, M., Wang, R., Wang, H., and Zang, H. (2022). Critical overview of hepatic factors that link non-alcoholic fatty liver disease and acute kidney injury: Physiology and therapeutic implications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012464"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Au-Yeung, K.K.W., Shang, Y., Wijerathne, C.U.B., Madduma Hewage, S., Siow, Y.L., and O, K. (2023). Acute kidney injury induces oxidative stress and hepatic lipid accumulation through AMPK signaling pathway. Antioxidants, 12.","DOI":"10.3390\/antiox12040883"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","article-title":"Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease","volume":"21","author":"Musso","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: An emerging driving force in chronic kidney disease","volume":"13","author":"Targher","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/toxsci\/kfac070","article-title":"Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination","volume":"189","author":"Frost","year":"2022","journal-title":"Toxicol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.2337\/dc15-1182","article-title":"Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities","volume":"39","author":"Musso","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"de Godoy Torso, N., Visacri, M.B., Quintanilha, J.C.F., Cursino, M.A., Pincinato, E.C., and Moriel, P. (2022). Assessment of renal function in head and neck cancer patients treated with cisplatin: Different biomarkers and acute kidney injury classifications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010141"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1535370217745302","article-title":"Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy","volume":"243","author":"George","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/cpt.606","article-title":"Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity","volume":"101","author":"George","year":"2017","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:57:19Z","timestamp":1759247839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":32,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199556"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199556","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}